Optimal use of intravenous landiolol in acute cardiac care

References

• Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics—2022 update: a report from the American heart association. Circulation. 2022;145(8). doi: 10.1161/CIR.0000000000001052
   PubMed Web of Science ®Google Scholar
• The top 10 causes of death [Internet]. [cited 2023 Aug 25]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
   Google Scholar
• Scott PA, Pancioli AM, Davis LA, et al. Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients. Stroke. 2002;33(11):2664–2669. doi: 10.1161/01.STR.0000035260.70403.88
   PubMed Web of Science ®Google Scholar
• Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–221. doi: 10.1177/1747493019897870
   PubMed Web of Science ®Google Scholar
• Induruwa I, Amis E, Hannon N, et al. The increasing burden of atrial fibrillation in acute Medical admissions, an opportunity to optimise stroke prevention. J Royal Coll Physicians Of Edinburgh. 2017;47(4):331–335. doi: 10.4997/jrcpe.2017.405
   PubMedGoogle Scholar
• Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure. J Am Coll Cardiol. 2014;63(12):1123–1133. doi: 10.1016/j.jacc.2013.11.053
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42(5):373–498. doi: 10.1093/eurheartj/ehaa612
   Web of Science ®Google Scholar
• Ibáñez B, Heusch G, Ovize M, et al. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015;65(14):1454–1471. doi: 10.1016/j.jacc.2015.02.032
   PubMed Web of Science ®Google Scholar
• Rienstra M, Damman K, Mulder BA, et al. Beta-blockers and outcome in heart failure and atrial fibrillation. JACC Heart Fail. 2013;1(1):21–28. doi: 10.1016/j.jchf.2012.09.002
   PubMed Web of Science ®Google Scholar
• Taylor SH, Silke B. Haemodynamic effects of beta-blockade in ischaemic heart failure. Lancet. 1981;318(8251):835–837. doi: 10.1016/S0140-6736(81)91105-3
   Google Scholar
• Waagstein F. Beta Blockers in heart failure. Cardiology. 1993;82(3):13–18. doi: 10.1159/000175929
   PubMedGoogle Scholar
• Yilmaz MB, Laribi S, Mebazaa A. Managing beta-blockers in acute heart failure: when to start and when to stop? Curr Heart Fail Rep. 2010;7(3):110–115. doi: 10.1007/s11897-010-0014-8
   PubMedGoogle Scholar
• Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting.BETA.-blocker, ONO-1101. Chem Pharm Bull. 1992;40(6):1462–1469. doi: 10.1248/cpb.40.1462
   PubMed Web of Science ®Google Scholar
• Kato K, Hayakawa H, Atarashi H, et al. Clinical effect of intravenous infusion of landiolol hydrochloride (ONO-1101) on paroxysmal atrial fibrillation and atrial flutter: a phase III, double-blind study in comparison with placebo. J Clin Ther Med. 1997;13:4903–4924.
   Google Scholar
• Yoshiya I, Ogawa R, Okumura F, et al. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia - a phase III, double-blind study in comparison with placebo. Rinsyoiyaku (J Clin Ther Med). 1997;13:4949–4978.
   Google Scholar
• Atarashi H. Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting β-blocker, in patients with cardiac arrhythmias. Clin Pharmacol Ther. 2000;68(2):143–150. doi: 10.1067/mcp.2000.108733
   PubMed Web of Science ®Google Scholar
• Matsuishi Y, Mathis BJ, Shimojo N, et al. Evaluating the therapeutic efficacy and safety of landiolol hydrochloride for management of arrhythmia in critical settings: review of the literature. VHRM. 2020; 16:p. 111–123.
   Google Scholar
• Stix G, Wolzt M, Domanovits H, et al. Open-label two-dose Pilot study of landiolol for the treatment of atrial fibrillation/atrial flutter in Caucasian patients. Circ J. 2019;84(1):33–42. doi: 10.1253/circj.CJ-19-0661
   PubMed Web of Science ®Google Scholar
• Lewis RV, McDevitt DG. Adverse reactions and interactions with β-Adrenoceptor blocking drugs. Medical Toxicology. 1986;1(5):343–361. doi: 10.1007/BF03259848
   PubMedGoogle Scholar
• Tsuchiya H, Mizogami M. Characteristic interactivity of landiolol, an ultra-short-acting highly selective β1-blocker, with biomimetic membranes: comparisons with β1-selective esmolol and non-selective propranolol and alprenolol. Front Pharmacol. 2013;4:4. doi: 10.3389/fphar.2013.00150
   PubMed Web of Science ®Google Scholar
• Domanovits H, Wolzt M, Stix G. Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting. Eur Heart J Suppl. 2018;20(suppl_A):A1–A3. doi: 10.1093/eurheartj/sux037
   PubMed Web of Science ®Google Scholar
• Nasrollahi-Shirazi S, Sucic S, Yang Q, et al. Comparison of the -adrenergic receptor antagonists landiolol and esmolol: receptor selectivity, partial agonism, and pharmacochaperoning actions. J Pharmacol Exp Ther. 2016;359(1):73–81. doi: 10.1124/jpet.116.232884
   PubMed Web of Science ®Google Scholar
• Shibata S, Okamoto Y, Endo S, et al. Direct effects of esmolol and landiolol on cardiac function, coronary vasoactivity, and ventricular electrophysiology in guinea-pig hearts. J Pharmacol Sci. 2012;118(2):255–265. doi: 10.1254/jphs.11202FP
   PubMed Web of Science ®Google Scholar
• Kakuta N, Kawano T, Tanaka K, et al. A comparison of landiolol and esmolol for attenuation of cardiovascular response and plasma renin activity against tracheal intubation with laryngoscopy. ASA Annual Meeting; New Orleans, Louisiana: Anesthesiology; 2005.
   Google Scholar
• Schnaubelt S, Eibensteiner F, Oppenauer J, et al. Hemodynamic and rhythmologic effects of push-dose landiolol in critical care—a retrospective cross-sectional study. Pharmaceuticals. 2023;16(2):134. doi: 10.3390/ph16020134
   Web of Science ®Google Scholar
• Krumpl G, Ulc I, Trebs M, et al. Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group. Eur J Pharmaceut Sci. 2016;92:64–73. doi: 10.1016/j.ejps.2016.06.022
   PubMed Web of Science ®Google Scholar
• Krumpl G, Ulč I, Trebs M, et al. Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults. BMC Pharmacol Toxicol. 2020;21(1):82. doi: 10.1186/s40360-020-00462-x
   PubMed Web of Science ®Google Scholar
• Patel PA, Tilley DG, Rockman HA. Beta-arrestin-mediated signaling in the heart. Circ J. 2008;72(11):1725–1729. doi: 10.1253/circj.CJ-08-0734
   PubMed Web of Science ®Google Scholar
• Suzuki K, Numaguchi A, Adachi YU, et al. Continuous administration of landiolol reduced QT dispersion in postoperative patients. J Clin Anesth. 2014;26(6):438–442. doi: 10.1016/j.jclinane.2014.01.017
   PubMed Web of Science ®Google Scholar
• Rehberg S, Joannidis M, Whitehouse T, et al. Landiolol for managing atrial fibrillation in intensive care. Eur Heart J Suppl. 2018;20(suppl_A):A15–A18. doi: 10.1093/eurheartj/sux039
   PubMed Web of Science ®Google Scholar
• Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. WJCCM. 2015;4(3):251. doi: 10.5492/wjccm.v4.i3.251
   Google Scholar
• Shiga T, Ikeda T, Shimizu W, et al. Efficacy and safety of landiolol in patients with ventricular tachyarrhythmias with or without renal impairment ― subanalysis of the J-Land II study ―. Circ Rep. 2020;2(8):440–445. doi: 10.1253/circrep.CR-20-0017
   PubMedGoogle Scholar
• McDonagh TA, Metra M, Adamo M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Tanai E, Frantz S. Pathophysiology of Heart failure. Compr Physiol. 2015 Dec 15;6(1):187–214. doi: 10.1002/cphy.c140055
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the framingham heart study. Circulation. 2003;107(23):2920–2925. doi: 10.1161/01.CIR.0000072767.89944.6E
   PubMed Web of Science ®Google Scholar
• Prins KW, Neill JM, Tyler JO, et al. Effects of beta-blocker withdrawal in acute decompensated heart failure. JACC Heart Fail. 2015;3(8):647–653. doi: 10.1016/j.jchf.2015.03.008
   PubMed Web of Science ®Google Scholar
• Abi Khalil C, Sulaiman K, Mahfoud Z, et al. Non-withdrawal of beta blockers in acute decompensated chronic and de novo heart failure with reduced ejection fraction in a prospective multicentre study of patients with acute heart failure in the Middle East. BMJ Open. 2017;7(7):e014915. doi: 10.1136/bmjopen-2016-014915
   PubMed Web of Science ®Google Scholar
• Tamaki Y, Yaku H, Morimoto T, et al. Lower in‐Hospital mortality with beta‐blocker use at admission in patients with acute decompensated heart failure. JAHA. 2021;10(13):e020012. doi: 10.1161/JAHA.120.020012
   Google Scholar
• Andersson B, Lomsky M, Waagstein F. The link between acute haemodynamic adrenergic beta-blockade and long-term effects in patients with heart failure: a study on diastolic function, heart rate and myocardial metabolism following intravenous metoprolol. Eur Heart J. 1993;14(10):1375–1385. doi: 10.1093/eurheartj/14.10.1375
   PubMed Web of Science ®Google Scholar
• Nagai R, Kinugawa K, Inoue H, et al. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land study). Circ J. 2013;77(4):908–916. doi: 10.1253/circj.CJ-12-1618
   PubMed Web of Science ®Google Scholar
• Kinugawa K, Nagai R, Inoue H, et al. Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: subgroup analysis of the J-Land study. Adv Ther. 2014;31(4):426–439. doi: 10.1007/s12325-014-0111-2
   PubMed Web of Science ®Google Scholar
• Wada Y, Aiba T, Tsujita Y, et al. Practical applicability of landiolol, an ultra-short-acting β1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction. J Arrhythm. 2016;32(2):82–88. doi: 10.1016/j.joa.2015.09.002
   PubMedGoogle Scholar
• Kiuchi S, Aikawa H, Hisatake S, et al. Efficacy of intravenous administration of landiolol in patients with acute heart failure and supraventricular tachyarrhythmia. J Clin Med Res. 2017;9(5):426–432. doi: 10.14740/jocmr2954w
   PubMedGoogle Scholar
• Oka E, Iwasaki Y, Maru E, et al. Differential effectiveness of landiolol between atrial fibrillation and atrial flutter/atrial tachycardia patients with left ventricular dysfunction. Circ J. 2019;83(4):793–800. doi: 10.1253/circj.CJ-18-1131
   PubMed Web of Science ®Google Scholar
• Yamashita T, Nakasu Y, Mizutani H, et al. A prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure – AF-CHF landiolol survey. J Cardiol. 2019;74(5):418–425. doi: 10.1016/j.jjcc.2019.05.012
   PubMed Web of Science ®Google Scholar
• Iwahashi N, Takahashi H, Abe T, et al. Urgent control of rapid atrial fibrillation by Landiolol in patients with acute decompensated heart failure with severely reduced ejection fraction. Circ Rep. 2019;1(10):422–430. doi: 10.1253/circrep.CR-19-0076
   PubMedGoogle Scholar
• Matsui Y, Suzuki A, Shiga T, et al. Effects of intravenous landiolol on heart rate and outcomes in patients with atrial tachyarrhythmias and acute decompensated heart failure: a single-center experience. Drugs Real World Outcomes. 2019;6(1):19–26. doi: 10.1007/s40801-019-0149-1
   PubMedGoogle Scholar
• Kobayashi S, Murakami W, Myoren T, et al. A low-dose β1-Blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation. Cardiology. 2014;127(2):105–113. doi: 10.1159/000355312
   PubMed Web of Science ®Google Scholar
• Shinohara M, Wada R, Yano K, et al. Comparison of landiolol and digoxin as an intravenous drug for controlling the heart rate in patients with atrial fibrillation and severely depressed left ventricular function. Int Heart J. 2020;61(5):944–950. doi: 10.1536/ihj.20-256
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Susa T, Tanaka T, et al. Low-dose β-blocker in combination with milrinone safely improves cardiac function and eliminates pulsus alternans in patients with acute decompensated heart failure. Circ J. 2012;76(7):1646–1653. doi: 10.1253/circj.CJ-12-0033
   PubMed Web of Science ®Google Scholar
• Adachi T, Sato A, Baba M, et al. Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure. Heart Vessels. 2014;29(4):464–469. doi: 10.1007/s00380-013-0377-3
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Myoren T, Kajii T, et al. Addition of a β1-blocker to milrinone treatment improves cardiac function in patients with acute heart failure and rapid atrial fibrillation. Cardiol. 2019;142(4):195–202. doi: 10.1159/000499400
   PubMed Web of Science ®Google Scholar
• Yoshima S. P2699Concomitant administration of landiolol and dobutamine in acute heart failure syndrome with atrial tachyarrhythmia. Eur Heart J. 2017;38(suppl_1):38. doi: 10.1093/eurheartj/ehx502.P2699
   PubMedGoogle Scholar
• Dabrowski W, Siwicka-Gieroba D, Piasek E, et al. Successful combination of landiolol and levosimendan in patients with decompensated heart failure: a report of 3 cases. Int Heart J. 2020;61(2):384–389. doi: 10.1536/ihj.19-420
   PubMed Web of Science ®Google Scholar
• Zeppenfeld K, Tfelt-Hansen J, De Riva M, et al. ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126. doi: 10.1093/eurheartj/ehac262
   PubMed Web of Science ®Google Scholar
• Miwa Y, Ikeda T, Mera H, et al. Effects of landiolol, an ultra-short-Acting.BETA.1-selective blocker, on electrical storm refractory to class III antiarrhythmic drugs. Circ J. 2010;74(5):856–863. doi: 10.1253/circj.CJ-09-0772
   PubMed Web of Science ®Google Scholar
• Ikeda T, Shiga T, Shimizu W, et al. Efficacy and safety of the ultra-short-acting β1-selective blocker landiolol in patients with recurrent hemodynamically unstable ventricular tachyarrhymias ― outcomes of J-Land II study ―. Circ J. 2019;83(7):1456–1462. doi: 10.1253/circj.CJ-18-1361
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2017;39(2):119–177. doi: 10.1093/eurheartj/ehx393
   Web of Science ®Google Scholar
• Sun B, Wang CY, Chen RR. Clinical efficacy and safety of early intravenous administration of beta-blockers in patients suffering from acute ST-Segment elevation myocardial infarction without heart failure undergoing primary percutaneous coronary intervention: a study-Level meta-analysis of randomized clinical trials. Cardiovasc Drugs Ther. 2023. doi: 10.1007/s10557-023-07448-x
   Web of Science ®Google Scholar
• Hanada K, Higuma T, Nishizaki F, et al. Randomized study on the efficacy and safety of landiolol, an ultra-short-Acting.BETA.1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J. 2012;76(2):439–445. doi: 10.1253/circj.CJ-11-0947
   PubMed Web of Science ®Google Scholar
• Hoshi T, Sato A, Nishina H, et al. Acute hemodynamic effects of landiolol, an ultra-short-acting beta-blocker, in patients with acute coronary syndrome: preliminary study. J Cardiol. 2012;60(4):252–256. doi: 10.1016/j.jjcc.2012.06.010
   PubMed Web of Science ®Google Scholar
• Kiyokuni M, Konishi M, Sakamaki K, et al. Beneficial effect of early infusion of landiolol, a very short-acting beta-1 adrenergic receptor blocker, on reperfusion status in acute myocardial infarction. Int J Cardiol. 2016;221:321–326. doi: 10.1016/j.ijcard.2016.07.076
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Osawa K, Miyoshi T, et al. Efficacy and safety of early intravenous landiolol on myocardial salvage in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention: a randomized study. Acta Medica Okayama. 2021;75(3): 289–297. doi: 10.18926/AMO/62220
   PubMed Web of Science ®Google Scholar
• Hollenberg SM, Singer M. Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol. 2021;18(6):424–434. doi: 10.1038/s41569-020-00492-2
   PubMed Web of Science ®Google Scholar
• Domizi R, Calcinaro S, Harris S, et al. Relationship between norepinephrine dose, tachycardia and outcome in septic shock: a multicentre evaluation. J Crit Care. 2020;57:185–190. doi: 10.1016/j.jcrc.2020.02.014
   PubMed Web of Science ®Google Scholar
• Walkey AJ, Hammill BG, Curtis LH, et al. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest. 2014;146(5):1187–1195. doi: 10.1378/chest.14-0003
   PubMed Web of Science ®Google Scholar
• Lescroart M, Pequignot B, Kimmoun A, et al. Beta-blockers in septic shock: what is new? J Intensive Med. 2022;2(3):150–155. doi: 10.1016/j.jointm.2022.01.004
   PubMedGoogle Scholar
• Hagiwara S, Iwasaka H, Maeda H, et al. Landiolol, an ultrashort-acting β1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model. 2009;31(5):515–520. doi: 10.1097/SHK.0b013e3181863689
   Google Scholar
• Morelli A, Ertmer C, Westphal M, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA. 2013;310(16):1683. doi: 10.1001/jama.2013.278477
   PubMed Web of Science ®Google Scholar
• Lee YR, Seth MS, Soney D, et al. Benefits of beta-blockade in sepsis and septic shock: a systematic review. Clin Drug Investig. 2019;39(5):429–440. doi: 10.1007/s40261-019-00762-z
   PubMed Web of Science ®Google Scholar
• Hasegawa D, Sato R, Prasitlumkum N, et al. Effect of ultrashort-acting β-blockers on mortality in patients with sepsis with persistent tachycardia despite initial resuscitation. Chest. 2021;159(6):2289–2300. doi: 10.1016/j.chest.2021.01.009
   PubMed Web of Science ®Google Scholar
• Kakihana Y, Nishida O, Taniguchi T, et al. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2020;8(9):863–872. doi: 10.1016/S2213-2600(20)30037-0
   PubMed Web of Science ®Google Scholar
• Ono K, Iwasaki Y, Akao M, et al. JCS/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias. J Arrhythm. 2022;38(6):833–973. doi: 10.1002/joa3.12714
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Susa T, Ishiguchi H, et al. A low-dose β1-blocker in combination with milrinone improves intracellular Ca2+ handling in failing cardiomyocytes by inhibition of milrinone-induced diastolic Ca2+ leakage from the Sarcoplasmic Reticulum. Ai X, editor. PLoS One. 2015;10(1):e0114314. doi: 10.1371/journal.pone.0114314
   PubMed Web of Science ®Google Scholar
• Feuerstein TJ, Krumpl G. The superselective β1-blocker landiolol enhances inotropy of endogenous and exogenous catecholamines in acute heart failure. Cardiol Cardiovasc Med. 2022;6(05):06. doi: 10.26502/fccm.92920291
   Google Scholar
• Bezati S, Velliou M, Polyzogopoulou E, et al. The role of landiolol in the management of atrial tachyarrhythmias in patients with acute heart failure and cardiogenic shock: case reports and review of literature. Eur Heart J Suppl. 2022;24(Supplement_D):D22–D33. doi: 10.1093/eurheartjsupp/suac024
   PubMed Web of Science ®Google Scholar
• Kimura-Kurosawa S, Kanaya N, Kamada N, et al. Cardioprotective effect and mechanism of action of landiolol on the ischemic reperfused heart. J Anesth. 2007;21(4):480–489. doi: 10.1007/s00540-007-0558-2
   PubMed Web of Science ®Google Scholar